Sermes CRO continues their international expansion process with their first Headquarters in Latin America (LATAM)

SERMES CRO continues their internationalization process with the opening of an office in Santiago de Chile consolidating their service´s coverage in LATAM.

Sermes CRO at the Colloquium-discussion “Sport YES, Injuries NO”, organized by the OAFI Foundation

Sermes CRO as a collaborator of the OAFI Foundation, has been invited on May 29, 2019, to the Colloquium-discussion “Sport YES, Injuries NO”, organized by the OAFI Foundation together with the medical services of Atlético de Madrid.

Sermes CRO awarded as the most Innovative company global supplier 2019 by MSD company (Merck Sharp and Dhome)

Sermes CRO Team, led by their CEO and founder Antonio Berlanga, accompanied by the responsible for clinical research and resposible of business development, has been awarded as the most company as the most Innovative company global supplier 2019 by MSD company (Merck Sharp and Dhome).

“Sermes CRO is committed to investing in the development of specific and technological areas”

From Sermes CRO years ago, we saw how this process came to stay and we bet on it. We invest in teams of specialized people to be able to create our own solutions and manage the information in an autonomous way. Nowadays, we have the necessary tools to give all kinds of services from our CRO/E-cro of high quality, budgetary efficiency and in the shortest time.

Sermes CRO: AEMPS approves the NC1 advance therapy drug for patients with chronic traumatic medullary injury

The NC1 cell therapy drug for patients with chronic traumatic spinal cord injury has been authorized by the AEMPS for public use at hospital use. NC1 has been developed by Dr. Vaquero and Dr. Zurita at Puerta de Hierro University Hospital with the collaboration in the clinical research of Sermes CRO and the Sermes Foundation.